James Huang - Aug 31, 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc. (CASI)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CASI	Common Stock	Purchase	$93.5K	+25K	+8.96%	$3.75^*	304K	Aug 31, 2022	See Footnote	F1, F2
transaction	CASI	Common Stock	Purchase	$44K	+11.8K	+3.89%	$3.72^*	316K	Sep 1, 2022	See Footnote	F2, F3
transaction	CASI	Common Stock	Purchase	$1.5K	+400	+0.13%	$3.74^*	316K	Sep 2, 2022	See Footnote	F2
holding	CASI	Common Stock						191	Aug 31, 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.69 to $3.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
F3	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.71 to $3.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.